Evidence map›Paper›PMID 35394258›Full record

ArticleInternational journal of hematology2022

Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.

Chikashi Yoshida, Takeshi Kondo, Tomoki Ito, Masahiro Kizaki, Kazuhiko Yamamoto, Toshihiro Miyamoto, Yasuyoshi Morita, Tetsuya Eto, Yuna Katsuoka, Naoki Takezako and 17 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Chikashi YoshidaDepartment of Hematology, National Hospital Organization Mito Medical Center, Ibaraki-machi, Japan. c.yoshida@mitomedical.org.
Takeshi KondoBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Tomoki ItoFirst Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Masahiro KizakiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Kazuhiko YamamotoDepartment of Hematology, Okayama City Hospital, Okayama, Japan.
Toshihiro MiyamotoMedicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yasuyoshi MoritaDivision of Hematology and Rheumatology, Department of Internal Medicine, Kindai University, Osaka, Japan.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Yuna KatsuokaDepartment of Hematology, Sendai Medical Center, National Hospital Organization, Sendai, Japan.
Naoki TakezakoDepartment of Hematology, Disaster Medical Center, Tokyo, Japan.
Nobuhiko UoshimaDepartment of Hematology, Kyoto Second Red Cross Hospital, Kyoto, Japan.
Kazunori ImadaDepartment of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Jun AndoDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Takuya KomenoDepartment of Hematology, National Hospital Organization Mito Medical Center, Ibaraki-machi, Japan.
Akio MoriBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Yuichi IshikawaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Atsushi SatakeFirst Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Junichi WatanabeDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Yoshiko KawakamiAbbVie GK, Tokyo, Japan.
Tetsuo MoritaAbbVie GK, Tokyo, Japan.
Ikue TaneikeAbbVie GK, Tokyo, Japan.
Masahiko NakayamaAbbVie GK, Tokyo, Japan.
Yinghui DuanAbbVie, Inc., North Chicago, IL, USA.
Belen Garbayo GuijarroAbbVie, Inc., Madrid, Spain.
Alexander DelgadoAbbVie, Inc., Singapore, Singapore.
Cynthia LlamasAbbVie, Inc., North Chicago, IL, USA.
Hitoshi KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) predominantly affects elderly adults, and its prognosis worsens with age. Treatment options for patients in Japan ineligible for intensive chemotherapy include cytarabine/aclarubicin ± granulocyte colony-stimulating factor (CA ± G), azacitidine (AZA), low-dose cytarabine (LDAC), targeted therapy, and best supportive care (BSC). The country's aging population and the evolving treatment landscape are contributing to a need to understand treatment pathways and associated outcomes. This retrospective chart review evaluated outcomes in patients across Japan with primary/secondary AML who were ineligible for intensive chemotherapy and began first-line treatment or BSC between 01/01/2015 and 12/31/2018. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS) and healthcare resource utilization (HRU). Of 199 patients (58% > 75 years), 121 received systemic therapy (38 CA ± G, 37 AZA, 7 LDAC, 39 other) and 78 received BSC. Median OS was 5.4, 9.2, 2.2, 3.8, and 2.2 months for CA ± G, AZA, LDAC, other systemic therapy, and BSC, respectively; median PFS was 3.4, 7.7, 1.6, 2.3, and 2.1 months, respectively. HRU rates were uniformly high, with > 80% patients hospitalized in each cohort. The poor clinical outcomes and high HRU among Japanese AML patients who are ineligible for intensive chemotherapy highlight an unmet need for novel therapies.

Indexed as

Leukemia, Myeloid, AcuteAgedAntineoplastic Combined Chemotherapy ProtocolsAzacitidineCytarabineHumansJapanRetrospective StudiesTreatment OutcomeAzacitidineCytarabineAclarubicin ± granulocyte colony-stimulating factorAcute myeloid leukemiaAzacitidineLow-dose cytarabine

Identifiers

PMID35394258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.